Cargando…

Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4

PURPOSE: Bone defects and nonunions are major clinical skeletal problems. Growth factors are commonly used to promote bone regeneration; however, the clinical impact is limited because the factors do not last long at a given site. The introduction of tissue engineering aimed to deter the diffusion o...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiozaki, Yasuyuki, Kitajima, Takashi, Mazaki, Tetsuro, Yoshida, Aki, Tanaka, Masato, Umezawa, Akihiro, Nakamura, Mariko, Yoshida, Yasuhiro, Ito, Yoshihiro, Ozaki, Toshifumi, Matsukawa, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626372/
https://www.ncbi.nlm.nih.gov/pubmed/23630418
http://dx.doi.org/10.2147/IJN.S44124
_version_ 1782266186728210432
author Shiozaki, Yasuyuki
Kitajima, Takashi
Mazaki, Tetsuro
Yoshida, Aki
Tanaka, Masato
Umezawa, Akihiro
Nakamura, Mariko
Yoshida, Yasuhiro
Ito, Yoshihiro
Ozaki, Toshifumi
Matsukawa, Akihiro
author_facet Shiozaki, Yasuyuki
Kitajima, Takashi
Mazaki, Tetsuro
Yoshida, Aki
Tanaka, Masato
Umezawa, Akihiro
Nakamura, Mariko
Yoshida, Yasuhiro
Ito, Yoshihiro
Ozaki, Toshifumi
Matsukawa, Akihiro
author_sort Shiozaki, Yasuyuki
collection PubMed
description PURPOSE: Bone defects and nonunions are major clinical skeletal problems. Growth factors are commonly used to promote bone regeneration; however, the clinical impact is limited because the factors do not last long at a given site. The introduction of tissue engineering aimed to deter the diffusion of these factors is a promising therapeutic strategy. The purpose of the present study was to evaluate the in vivo osteogenic capability of an engineered bone morphogenetic protein-4 (BMP4) fusion protein. METHODS: BMP4 was fused with a nanosized carrier, collagen-binding domain (CBD), derived from fibronectin. The stability of the CBD-BMP4 fusion protein was examined in vitro and in vivo. Osteogenic effects of CBD-BMP4 were evaluated by computer tomography after intramedullary injection without a collagen–sponge scaffold. Recombinant BMP-4, CBD, or vehicle were used as controls. Expressions of bone-related genes and growth factors were compared among the groups. Osteogenesis induced by CBD-BMP4, BMP4, and CBD was also assessed in a bone-defect model. RESULTS: In vitro, CBD-BMP4 was retained in a collagen gel for at least 7 days while BMP4 alone was released within 3 hours. In vivo, CBD-BMP4 remained at the given site for at least 2 weeks, both with or without a collagen–sponge scaffold, while BMP4 disappeared from the site within 3 days after injection. CBD-BMP4 induced better bone formation than BMP4 did alone, CBD alone, and vehicle after the intramedullary injection into the mouse femur. Bone-related genes and growth factors were expressed at higher levels in CBD-BMP4-treated mice than in all other groups, including BMP4-treated mice. Finally, CBD-BMP4 potentiated more bone formation than did controls, including BMP4 alone, when applied to cranial bone defects without a collagen scaffold. CONCLUSION: Altogether, nanocarrier-CBD enhanced the retention of BMP4 in the bone, thereby promoting augmented osteogenic responses in the absence of a scaffold. These results suggest that CBD-BMP4 may be clinically useful in facilitating bone formation.
format Online
Article
Text
id pubmed-3626372
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36263722013-04-29 Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4 Shiozaki, Yasuyuki Kitajima, Takashi Mazaki, Tetsuro Yoshida, Aki Tanaka, Masato Umezawa, Akihiro Nakamura, Mariko Yoshida, Yasuhiro Ito, Yoshihiro Ozaki, Toshifumi Matsukawa, Akihiro Int J Nanomedicine Original Research PURPOSE: Bone defects and nonunions are major clinical skeletal problems. Growth factors are commonly used to promote bone regeneration; however, the clinical impact is limited because the factors do not last long at a given site. The introduction of tissue engineering aimed to deter the diffusion of these factors is a promising therapeutic strategy. The purpose of the present study was to evaluate the in vivo osteogenic capability of an engineered bone morphogenetic protein-4 (BMP4) fusion protein. METHODS: BMP4 was fused with a nanosized carrier, collagen-binding domain (CBD), derived from fibronectin. The stability of the CBD-BMP4 fusion protein was examined in vitro and in vivo. Osteogenic effects of CBD-BMP4 were evaluated by computer tomography after intramedullary injection without a collagen–sponge scaffold. Recombinant BMP-4, CBD, or vehicle were used as controls. Expressions of bone-related genes and growth factors were compared among the groups. Osteogenesis induced by CBD-BMP4, BMP4, and CBD was also assessed in a bone-defect model. RESULTS: In vitro, CBD-BMP4 was retained in a collagen gel for at least 7 days while BMP4 alone was released within 3 hours. In vivo, CBD-BMP4 remained at the given site for at least 2 weeks, both with or without a collagen–sponge scaffold, while BMP4 disappeared from the site within 3 days after injection. CBD-BMP4 induced better bone formation than BMP4 did alone, CBD alone, and vehicle after the intramedullary injection into the mouse femur. Bone-related genes and growth factors were expressed at higher levels in CBD-BMP4-treated mice than in all other groups, including BMP4-treated mice. Finally, CBD-BMP4 potentiated more bone formation than did controls, including BMP4 alone, when applied to cranial bone defects without a collagen scaffold. CONCLUSION: Altogether, nanocarrier-CBD enhanced the retention of BMP4 in the bone, thereby promoting augmented osteogenic responses in the absence of a scaffold. These results suggest that CBD-BMP4 may be clinically useful in facilitating bone formation. Dove Medical Press 2013 2013-04-09 /pmc/articles/PMC3626372/ /pubmed/23630418 http://dx.doi.org/10.2147/IJN.S44124 Text en © 2013 Shiozaki et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Shiozaki, Yasuyuki
Kitajima, Takashi
Mazaki, Tetsuro
Yoshida, Aki
Tanaka, Masato
Umezawa, Akihiro
Nakamura, Mariko
Yoshida, Yasuhiro
Ito, Yoshihiro
Ozaki, Toshifumi
Matsukawa, Akihiro
Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4
title Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4
title_full Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4
title_fullStr Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4
title_full_unstemmed Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4
title_short Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4
title_sort enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626372/
https://www.ncbi.nlm.nih.gov/pubmed/23630418
http://dx.doi.org/10.2147/IJN.S44124
work_keys_str_mv AT shiozakiyasuyuki enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT kitajimatakashi enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT mazakitetsuro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT yoshidaaki enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT tanakamasato enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT umezawaakihiro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT nakamuramariko enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT yoshidayasuhiro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT itoyoshihiro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT ozakitoshifumi enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4
AT matsukawaakihiro enhancedinvivoosteogenesisbynanocarrierfusedbonemorphogeneticprotein4